Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, James N. Kochenderfer, Jesús G. Berdeja et al.|New England Journal of Medicine|2019Cited by 1.7k
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G. Richardson, Irene M. Ghobrial, Noopur Raje et al.|New England Journal of Medicine|2022Cited by 457
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE studyHagop M. Kantarjian, Anjali S. Advani, Daniel J. DeAngelo et al.|Cancer|2019Cited by 327
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Shaji Kumar, Jeffrey Matous et al.|Nature Medicine|2023Cited by 239
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsMark R. Litzow, Martin S. Tallman, Zhuoxin Sun et al.|New England Journal of Medicine|2024Cited by 213